On the stock market since 2022, it operates in the world of raw materials. It has 13 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 13% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $828K a year. A small number, but proof the product has real buyers.
A loss of $8.3M against $828K in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 10 sells against just 3 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, RMRI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RMRI is a high-risk stock — not yet profitable, and its future rides on its product catching on.